Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Xenon Pharmaceuticals stock

Learn how to easily invest in Xenon Pharmaceuticals stock.

Xenon Pharmaceuticals is a biotechnology business based in the US. Xenon Pharmaceuticals shares (XENE) are listed on the NASDAQ and all prices are listed in US Dollars. Xenon Pharmaceuticals employs 149 staff and has a trailing 12-month revenue of around $13.2 million.

How to buy Xenon Pharmaceuticals stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – XENE. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award

eToro


  • Easy to use platform with low fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience

Robinhood


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Xenon Pharmaceuticals stock price (NASDAQ: XENE)

Use our graph to track the performance of XENE stocks over time.

Xenon Pharmaceuticals shares at a glance

Information last updated 2023-02-02.
Latest market close$39.19
52-week range$24.94 - $41.39
50-day moving average $37.28
200-day moving average $34.57
Wall St. target price$50.67
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.56

Buy Xenon Pharmaceuticals stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
eToro
Stocks, Options, ETFs, Cryptocurrency
$0
$10
FINDER EXCLUSIVE: Get $15
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Xenon Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Xenon Pharmaceuticals price performance over time

Historical closes compared with the close of $39.19 from 2023-02-03

1 week (2023-01-31) 0.26%
1 month (2023-01-06) 2.43%
3 months (2022-11-07) 12.71%
6 months (2022-08-05) 1.87%
1 year (2022-02-03) N/A
2 years (2021-02-05) 142.81%
3 years (2020-02-07) 166.06%
5 years (2018-02-07) 1,061.19%

Xenon Pharmaceuticals financials

Revenue TTM $13.2 million
Gross profit TTM $-57,026,000
Return on assets TTM -13.3%
Return on equity TTM -22.66%
Profit margin 0%
Book value $12.04
Market capitalisation $2.4 billion

TTM: trailing 12 months

Xenon Pharmaceuticals share dividends

We're not expecting Xenon Pharmaceuticals to pay a dividend over the next 12 months.

Xenon Pharmaceuticals share price volatility

Over the last 12 months, Xenon Pharmaceuticals's shares have ranged in value from as little as $24.94 up to $41.39. A popular way to gauge a stock's volatility is its "beta".

XENE.US volatility(beta: 1.36)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xenon Pharmaceuticals's is 1.3634. This would suggest that Xenon Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Xenon Pharmaceuticals overview

Xenon Pharmaceuticals Inc. , a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1. 6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc.

Frequently asked questions

What percentage of Xenon Pharmaceuticals is owned by insiders or institutions?
Currently 1.705% of Xenon Pharmaceuticals shares are held by insiders and 95.769% by institutions.
How many people work for Xenon Pharmaceuticals?
Latest data suggests 149 work at Xenon Pharmaceuticals.
When does the fiscal year end for Xenon Pharmaceuticals?
Xenon Pharmaceuticals's fiscal year ends in December.
Where is Xenon Pharmaceuticals based?
Xenon Pharmaceuticals's address is: 3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8
What is Xenon Pharmaceuticals's ISIN number?
Xenon Pharmaceuticals's international securities identification number is: CA98420N1050
What is Xenon Pharmaceuticals's CUSIP number?
Xenon Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 98420N105

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site